Coapting Cost and Clinical Outcomes in Transcatheter Intervention for Secondary Mitral Regurgitation

Robert O. Bonow; Daniel B. Mark; Patrick T. O'Gara

doi:10.1161/CIRCULATIONAHA.119.043408

Coapting Cost and Clinical Outcomes in Transcatheter Intervention for Secondary Mitral Regurgitation

Robert O. Bonow, Daniel B. Mark, Patrick T. O'Gara

Medicine, Cardiology Division

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	1892-1894
Number of pages	3
Journal	Circulation
Volume	140
Issue number	23
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.119.043408
State	Published - Dec 3 2019

Funding

Dr Mark reports grants from Eli Lilly & Company, Gilead, AstraZeneca, Bristol Myers Squibb, Merck & Company, and Oxygen Therapeutics and consulting fees from Medtronic and Janssen, outside the submitted work. The other authors report no conflicts.

Keywords

Editorials
cost effeciveness
heart failure
mitral valve insufficiency
replacement
ventricular remodeling

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Physiology (medical)

Access to Document

10.1161/CIRCULATIONAHA.119.043408

Cite this

@article{b4a2ccd211984d9f8c045a75397bcc28,

title = "Coapting Cost and Clinical Outcomes in Transcatheter Intervention for Secondary Mitral Regurgitation",

keywords = "Editorials, cost effeciveness, heart failure, mitral valve insufficiency, replacement, ventricular remodeling",

author = "Bonow, {Robert O.} and Mark, {Daniel B.} and O'Gara, {Patrick T.}",

note = "Funding Information: Dr Mark reports grants from Eli Lilly & Company, Gilead, AstraZeneca, Bristol Myers Squibb, Merck & Company, and Oxygen Therapeutics and consulting fees from Medtronic and Janssen, outside the submitted work. The other authors report no conflicts.",

year = "2019",

month = dec,

day = "3",

doi = "10.1161/CIRCULATIONAHA.119.043408",

language = "English (US)",

volume = "140",

pages = "1892--1894",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

number = "23",

}

TY - JOUR

T1 - Coapting Cost and Clinical Outcomes in Transcatheter Intervention for Secondary Mitral Regurgitation

AU - Bonow, Robert O.

AU - Mark, Daniel B.

AU - O'Gara, Patrick T.

N1 - Funding Information: Dr Mark reports grants from Eli Lilly & Company, Gilead, AstraZeneca, Bristol Myers Squibb, Merck & Company, and Oxygen Therapeutics and consulting fees from Medtronic and Janssen, outside the submitted work. The other authors report no conflicts.

PY - 2019/12/3

Y1 - 2019/12/3

KW - Editorials

KW - cost effeciveness

KW - heart failure

KW - mitral valve insufficiency

KW - replacement

KW - ventricular remodeling

UR - http://www.scopus.com/inward/record.url?scp=85075961278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075961278&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.119.043408

DO - 10.1161/CIRCULATIONAHA.119.043408

M3 - Review article

C2 - 31564139

AN - SCOPUS:85075961278

SN - 0009-7322

VL - 140

SP - 1892

EP - 1894

JO - Circulation

JF - Circulation

IS - 23

ER -

Coapting Cost and Clinical Outcomes in Transcatheter Intervention for Secondary Mitral Regurgitation

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this